Shenzhen Haibin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd. (Stock Code: 600380). Established in 1989, the company officially commenced production in 1992 with a registered capital of RMB 700 million. The plant covers an area of 16,000 square meters, with a building area of 26,800 square meters. The company is located in Yantian District, Shenzhen—a National Ecological and Environmental Protection Demonstration Zone. Backed by Wutong Mountain and facing Dapeng Bay, the company is endowed with exceptional natural resources. By land, it connects directly to Hong Kong via the Shatoujiao Checkpoint. It is also adjacent to the world-class container port - Yantian Port, boasting shipping routes that reach over 80 countries and regions.

Shenzhen Haibin Pharmaceutical Co., Ltd. leases a part of the premises from Xinxiang Haibin Pharmaceutical Co., Ltd. (located in the Dedong Block, High-Tech Industrial Development Zone, Xinxiang City, Henan Province). This includes Building 4, the west section of Building 5, Building 6, parts ofBuildings 10 and 12, parts of Areas A and H (tank farm), and Building 16, to establish the off-site Workshop 6. The workshop officially commenced production in 2019 and operates under the full administration of Shenzhen Haibin Pharmaceutical Co., Ltd. It covers an area of approximately 6,583 square meters, with a building area of about 11,492 square meters.

 Since its establishment, Shenzhen Haibin Pharmaceutical Co., Ltd. has consistently adhered to its core values of diligence, innovation, rigor, and efficiency, along with a people-oriented business philosophy. After years of dedicated effort, the company has achieved remarkable milestones and received a series of prestigious honors, including "National High-Tech Enterprise," "National Green Factory," and "National Intellectual Property Advantage Enterprise." Today, the company has grown into a modern pharmaceutical enterprise with over 500 employees and an annual revenue exceeding RMB 1 billion.

 Shenzhen Haibin Pharmaceutical Co., Ltd. primarily produces antibiotics. Its business scope covers chemical APIs and finished dosage forms and Chinese patent medicines. The company operates multiple GMP-compliant production lines, including those for carbapenem APIs and finished products, lyophilized APIs, general chemical APIs, and conventional oral solid dosage forms. Major products include Meropenem, Imipenem, Cilastatin Sodium, PAINON®, Suneng®, Desloratadine Tablets, and Irbesartan Tablets. The company has built an annual production capacity of 80 million vials of powder for injection, 100 million tablets, and 100 million capsules, supported by a fully integrated API production chain.

 The development of new products and process optimization are the driving forces behind our sustainable growth and represent our core competencies. In 1999, Shenzhen Haibin Pharmaceutical Co., Ltd. began researching a new generation of highly effective broad-spectrum antibacterial drugs—carbapenem antibiotics—making them a key R&D focus. Currently, the company has completed process research for products such as Meropenem, Imipenem and Biapenem, while significantly innovating and optimizing the API production processes. For instance, the initial development route for Meropenem was complex and the process was unstable. Early production costs were high, making it commercially unviable. Through years of continuous dedication by our R&D team, we not only reduced production costs but also further enhanced product quality. As a result, both the API and its finished dosage forms now meet the European Pharmacopoeia (Ph. Eur.) and United States Pharmacopeia (USP) standards, greatly boosting their market competitiveness. The company now holds multiple Chinese and international patents for Meropenem production processes. As flagship products in today's antibiotic field, carbapenem antibiotics exhibit remarkable efficacy against severe and refractory infections. Their successful development has not only created new, long-lasting profit growth engines for the company but will undoubtedly write a new chapter in China's antibiotic industry.

 "Rooted in China, reaching the world" is a pivotal strategic goal of Shenzhen Haibin Pharmaceutical Co., Ltd. Through unremitting efforts, the company began exporting Meropenem APIs in 2003, with export volumes growing year by year. Our products are now exported to Europe, Southeast Asia, Africa, the Middle East, South America, and beyond. Subsequently, Imipenem and Cilastatin Sodium APIs also successfully entered overseas markets such as India and Brazil.

 Expanding our market presence and exporting products to regulated markets, such as Europe and the United States, remains our ongoing objective. Obtaining EU certifications and U.S. FDA approval is the essential pathway to achieving this. In December 2006, we signed a cooperation agreement with a German company regarding EU registration and certification, marking the prologue of our entry into European and American markets. In 2012, our sterile Meropenem APIs and sterile finished dosage forms successfully obtained EU-GMP certificate.

 Quality is our lifeline. Shenzhen Haibin Pharmaceutical Co., Ltd. has established a robust quality management system fully compliant with GMP requirements. The Quality Department oversees product testing and the operation of the company’s quality assurance system, with quality management personnel accounting for approximately 20% of the total workforce. The laboratory is equipped with specialized functional rooms, such as sterility testing rooms and microbial limit testing rooms. It also utilizes advanced analytical instruments, including HPLC, GC, and IR spectrophotometer, to fully satisfy all product testing requirements.

 As an active member of the pharmaceutical industry, we bear the responsibility to advance the pharmaceutical sector and safeguard human health. We firmly believe that by maintaining our goal of "sincere dedication to the cause of human health," upholding our work style of "care, compassion, rigor, and diligence," and continuously pursuing innovation and excellence, Shenzhen Haibin Pharmaceutical Co., Ltd. will undoubtedly shine as a brilliant star in China’s pharmaceutical industry.